FRX Forest Road Acquisition Corp

In the news release, Forest Laboratories, Inc. (NYSE:FRX) and Cypress Bioscience, Inc. (NASDAQ:CYPB) Announce Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia, issued earlier today by Forest Laboratories, Inc. and Cypress Biosciences, Inc. over PR Newswire, the third footnote should read "Last Observation Carry-forward (LOCF) is an analysis in which observations are carried forward to the last time point for patients who dropped out. The LOCF analysis treats the carried-forward data as observed data at the last time point." rather than "Patient Global Impression of Change (PGIC) is a patient reported periodic assessment of their perception of change in their condition." as incorrectly transmitted by PR Newswire. PRNewswire - Sept. 28 DATASOURCE: Forest Laboratories, Inc.; Cypress Biosciences, Inc.

Copyright